The UK's National Institute for Health and Care Excellence (NICE) has initially recommended against NHS reimbursement of Roche's breast cancer treatment Perjeta (pertuzumab). However, in the case of Perjeta this is all something of a moot point. Whether NICE recommends Perjeta will all come down to the patient access scheme it negotiates with Roche. Read more. (Source: FirstWord Pharma, 8/07/13).
You are here: / Can Roche’s funding scheme get a NICE recommendation for Perjeta?